Ventyx Biosciences Inc.
VTYX | NASDAQ
$14
$0 (0.00%)
At close: Mar 6, 2026, 9:30 AM ET
Fiscal Year Period Ending | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 | FY 2019 Dec 30, 2019 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -148.45M | -207.99M | -113.14M | -67.15M | -7.05M | -4.18M |
Interest Income | 13.42M | 15.07M | 4.67M | 78K | 358 | 146 |
Pretax Income | -135.12M | -192.96M | -108.43M | -83.75M | -28.17M | -4.33M |
Net Income | -135.12M | -192.96M | -108.43M | -83.75M | -28.17M | -4.47M |
Selling & General & Admin | 31.45M | 32.23M | 25.4M | 8.67M | 684K | 628K |
Research & Development | 117M | 175.77M | 87.74M | 58.48M | 6.37M | 3.55M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 148.45M | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
Interest Expense | n/a | n/a | n/a | 99K | 358K | 146K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 148.45M | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 68.48M | 58.54M | 52.47M | 50.41M | 50.3M | 1.96M |
Shares Outstanding (Diluted) | 68.48M | 58.54M | 52.47M | 50.41M | 50.3M | 1.96M |
EPS (Basic) | -1.97 | -3.30 | -2.06 | -1.69 | -0.56 | -2.29 |
EPS (Diluted) | -1.97 | -3.30 | -2.06 | -1.69 | -0.56 | -2.29 |
EBITDA | -147.1M | -207.05M | -112.67M | -83.62M | n/a | -1K |
EBIT | -148.45M | -207.99M | -113.14M | -83.65M | -7.05M | -4.18M |
Depreciation & Amortization | 1.35M | 941K | 470K | 30K | 7.05M | 4.18M |
Add to Watchlist
Select watchlists to add or remove VTYX